Effects of Moderate Consumption of Lean Fish on Weight Loss

Effects of Moderate Consumption Lean Fish on Weight Loss of Overweight and Obese Women During a Weight Loss Program, a 24 Week Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03120429

Enrollment

120

Registered

2017-04-19

Start date

2017-06-25

Completion date

2019-10-13

Last updated

2019-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

lean fish, weight loss, Diet

Brief summary

the aim of present study is to compare the specific effects moderate consumption of lean fish on weight loss of healthy obese and overweight female adults, while participants follow energy-restricted diets also to investigate the effects of this intervention on carbohydrate and lipid profiles, as cardiometabolic risk factors.

Interventions

BEHAVIORALFish group

Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal

BEHAVIORALControl group

Control group will have hypo-energetic diet in which subjects have no seafood.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* female * 18-45 years of age. * Body mass index (BMI) between 27.5-35 kg/m² * Must be able to have moderate exercise. * Must be interested to lose weight

Exclusion criteria

* Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * Taking medications that could affect metabolism or change body weight. * Report heart problems, chest pain, and cancer within the last five years. * Use of supplements containing n-3 fatty acids, calcium or vitamin-D during the last 3 months. * Consumption of fish and sea foods regularly * Smoking * Menopause * Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Design outcomes

Primary

Measure	Time frame	Description
weight loss	24 Weeks	kg

Secondary

Measure	Time frame	Description
fasting plasma glucose	24 Weeks	mmol/l
serum insulin level	24 Weeks	mU/l
insulin resistance (HOMA-IR)	24 Weeks	score
waist circumference	24 Weeks	cm
lipid profiles	24 Weeks	mmol/l
liver enzymes (SGOT, SGPT)	24 Weeks	U/l
glycosylated hemoglobin (HbA1c)	24 Weeks	percentage (%)

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026